Sex- and time-dependent patterns in risk factors of end-stage renal disease: A large Austrian cohort with up to 20 years of follow-up

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Pscheidt, Constanze ^a,b   Nagel, Gabriele ^a,b   Zitt, Emanuel ^c   Kramar, Reinhard ^d   Concin, Hans ^a   Lhotta, Karl ^c  

^a AGENCY FOR PREVENTIVE AND SOCIAL MEDICINE   (Austria)

^b UNIVERSITY OF ULM   (Germany)

^c Feldkirch Academic Teaching Hospital Vorarlberg Institute for Vascular Investigation and Treatment   (Austria)

^d Vorarlberg Institute for Vascular Investigation and Treatment Academic Teaching Hospital Feldkirch ^*  (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ARTICLE; AUSTRIAN; BODY MASS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; METABOLISM; MIDDLE AGED; OBESITY; ONSET AGE; POPULATION RESEARCH; PREHYPERTENSION; PREVALENCE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; RISK FACTOR; SEX DIFFERENCE; SMOKING; SYSTOLIC BLOOD PRESSURE; TIME; BLOOD; BLOOD PRESSURE; HEMODIALYSIS; KIDNEY FAILURE, CHRONIC; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL; FEMALE; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; SEX FACTORS; TRIGLYCERIDES;

EID: 84943275133     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135052     Document Type: Article

References (33)

1. Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet. 2015.
2. Turin TC, Tonelli M, Manns BJ, Ahmed SB, Ravani P, James M, et al. Lifetime risk of ESRD. Journal of the American Society of Nephrology: JASN. 2012;23(9):1569-78. doi: 10.1681/ASN.2012020164 PMID: 22904351
3. Chang TI, Li S, Chen SC, Peralta CA, Shlipak MG, Fried LF, et al. Risk factors for ESRD in individuals with preserved estimated GFR with and without albuminuria: results from the Kidney Early Evaluation Program (KEEP). American journal of kidney diseases: the official journal of the National Kidney Foundation. 2013;61 (4 Suppl2):S4-11.
4. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney international. 2011;80(12):1258-70. doi: 10. 1038/ki.2011.368 PMID: 21993585
5. Eckardt KU, Coresh J, Devuyst O, Johnson RJ, Kottgen A, Levey AS, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013;382(9887):158-69. doi: 10.1016/S0140-6736 (13) 60439-0 PMID: 23727165
6. Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Archives of internal medicine. 2009;169(4):342-50. doi: 10.1001/archinternmed.2008. 605 PMID: 19237717
7. Kastarinen M, Juutilainen A, Kastarinen H, Salomaa V, Karhapaa P, Tuomilehto J, et al. Risk factors for end-stage renal disease in a community-based population: 26-year follow-up of 25, 821 men and women in eastern Finland. Journal of internal medicine. 2010;267(6):612-20. doi: 10.1111/j.1365-2796.2009.02197.x PMID: 20210838
8. Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension. 2003;41(6):1341-5. PMID: 12707291
9. McMahon GM, Preis SR, Hwang SJ, Fox CS. Mid-Adulthood Risk Factor Profiles for CKD. Journal of the American Society of Nephrology: JASN. 2014.
10. Nagel G, Zitt E, Peter R, Pompella A, Concin H, Lhotta K. Body mass index and metabolic factors predict glomerular filtration rate and albuminuria over 20 years in a high-risk population. BMC nephrology. 2013;14(1):177.
11. Watanabe H, Obata H, Watanabe T, Sasaki S, Nagai K, Aizawa Y. Metabolic syndrome and risk of development of chronic kidney disease: the Niigata preventive medicine study. Diabetes/metabolism research and reviews. 2010;26(1):26-32. doi: 10.1002/dmrr.1058 PMID: 20014332
12. Sun F, Tao Q, Zhan S. Metabolic syndrome and the development of chronic kidney disease among 118 924 non-diabetic Taiwanese in a retrospective cohort. Nephrology (Carlton, Vic). 2010;15(1):84-92.
13. Tozawa M, Iseki C, Tokashiki K, Chinen S, Kohagura K, Kinjo K, et al. Metabolic syndrome and risk of developing chronic kidney disease in Japanese adults. Hypertension research: official journal of the Japanese Society of Hypertension. 2007;30(10):937-43.
14. Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clinical journal of the American Society of Nephrology: CJASN. 2011;6(10):2364-73. doi: 10.2215/CJN.02180311 PMID: 21852664
15. Wimmer F, Oberaigner W, Kramar R, Mayer G. Regional variability in the incidence of end-stage renal disease: an epidemiological approach. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association. 2003;18(8):1562-7.
16. Ulmer H, Kelleher C, Diem G, Concin H. Long-term tracking of cardiovascular risk factors among men and women in a large population-based health system: the Vorarlberg Health Monitoring & Promotion Programme. European heart journal. 2003;24(11):1004-13. PMID: 12788300
17. Klenk J, Nagel G, Ulmer H, Strasak A, Concin H, Diem G, et al. Body mass index and mortality: results of a cohort of 184, 697 adults in Austria. European journal of epidemiology. 2009;24(2):83-91. doi: 10. 1007/s10654-009-9312-4 PMID: 19184464
18. WHO. BMI classification [21.06.2014]. Available: http://apps.who.int/bmi/index.jsp?introPage = intro 3.html.
19. Society AD. Fasting Plasma Glucose American Diabetes Society [19.06.2014]. Cut-off Points for Diabetes Categories]. Available from: http://www.diabetes.org/diabetes-basics/diagnosis/.
20. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-52. PMID: 14656957
21. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421. PMID: 12485966
22. Vivante A, Golan E, Tzur D, Leiba A, Tirosh A, Skorecki K, et al. Body mass index in 1.2 million adolescents and risk for end-stage renal disease. Archives of internal medicine. 2012;172(21):1644-50. PMID: 23108588
23. Panwar B, Hanks LJ, Tanner RM, Muntner P, Kramer H, McClellan WM, et al. Obesity, metabolic health, and the risk of end-stage renal disease. Kidney international. 2014.
24. Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Archives of internal medicine. 2005;165(8):923-8. PMID: 15851645
25. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and endstage renal disease in men. The New England journal of medicine. 1996;334(1):13-8. PMID: 7494564
26. Boucquemont J, Heinze G, Jager KJ, Oberbauer R, Leffondre K. Regression methods for investigating risk factors of chronic kidney disease outcomes: the state of the art. BMC nephrology. 2014;15:45. doi: 10.1186/1471-2369-15-45 PMID: 24628838
27. Rahman M, Yang W, Akkina S, Alper A, Anderson AH, Appel LJ, et al. Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study. Clinical journal of the American Society of Nephrology: CJASN. 2014;9(7):1190-8. doi: 10.2215/CJN.09320913 PMID: 24832097
28. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney international. 2000;58(1):293-301. PMID: 10886574
29. Balogun WO, Adeleye JO, Akinlade KS, Adedapo KS, Kuti M. Frequent occurrence of high gamma-glutamyl transferase and alanine amino transferase among Nigerian patients with type 2 diabetes. African journal of medicine and medical sciences. 2008;37(2):177-83. PMID: 18939403
30. Meisinger C, Lowel H, Heier M, Schneider A, Thorand B. Serum gamma-glutamyltransferase and risk of type 2 diabetes mellitus in men and women from the general population. Journal of internal medicine. 2005;258(6):527-35. PMID: 16313476
31. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163, 944 Austrian adults. Circulation. 2005;112(14):2130-7. PMID: 16186419
32. Targher G, Kendrick J, Smits G, Chonchol M. Relationship between serum gamma-glutamyltransferase and chronic kidney disease in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006. Nutrition, metabolism, and cardiovascular diseases: NMCD. 2010;20(8):583-90. doi: 10.1016/j.numecd.2009.05.012 PMID: 19699624
33. Ryu S, Chang Y, Kim DI, Kim WS, Suh BS. gamma-Glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. Clinical chemistry. 2007;53(1):71-7. PMID: 17110470